10x Genomics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by 10x Genomics, Inc. on August 6, 2026. The filing announces the Company's financial results for the quarter ended June 30, 2026, pursuant to Item 2.02. The full details of the results are contained in a press release attached as Exhibit 99.1.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the attached press release (Exhibit 99.1), which is not included in the source text.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. Investors must refer to the attached press release for comparative financial analysis.
Guidance, Outlook, and Risks
The filing text does not include management commentary, forward-looking guidance, specific risks, contingencies, or unusual items. The document serves solely as a notification that the press release containing this information has been issued.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific Q2 2026 revenue and earnings figures.
- Verify year-over-year and quarter-over-quarter growth rates in the press release.
- Check for any updated full-year 2026 financial guidance provided in the press release.
- Confirm the status of the Company's cash position and debt obligations as detailed in the press release.